Sanofi to start insulin supplies to EU market from Russian plant

15 May 2017

French pharma major Sanofi (Euronext: SAN) has announced it is ready to start supplying insulin, which is produced at its factory in the Russian Orel region, to the European market, reports The Pharma Letter’s local correspondent. Planned volume of supplies is currently not disclosed.

According to Oksana Monzh, general manager of the prescription business of Sanofi, the current capacities of the Orel are sufficient to fully meet the needs of Russian patients, and to start deliveries to foreign markets. In 2015, the Orel plant received a European Good Manufacturing Practices (GMP) certificate, which allowed it to start the supplies of its insulin to abroad.

At the same time Ms Monzh expressed concerns about the restrictions that are created by the Russian government within the interests of domestic pharmaceutical producers, and in particular during the organization of state tenders for public procurement of drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK